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Anti-GQ1b IgG antibody syndrome: a case report
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Anti-GQ1b antibody syndrome is a term used for describing different condi-
tions that are believed to have a common underlying autoimmune mechanism
and positive anti-GQ1b IgG antibodies in serum. The aim was to present chal-
lenges in diagnosis and treatment of a young 31-year old patient with overlap-
ping Guillain-Barré syndrome and Miller Fisher syndrome who was treated
with plasma exchange and intravenous immunoglobulins (IVIg) which gradual-
ly resulted in almost full neurological recovery.
Prikaz bolesnika
Sindrom anti-GQ1b protutijela pojam je koji se koristi za opis razli~itih stanja
za koja se smatra da imaju zajedni~ki predle`e}i autoimuni mehanizam nastan-
ka i pozitivna anti-GQ1b protutijela u serumu. Cilj ovog rada bio je prikazati iza-
zove u dijagnostici i lije~enju mladog 31-godi{njeg bolesnika s preklapaju}im
Guillain-Barréovim sindromom i Miller Fisherovim sindromom koji je lije~en
plazmaferezom i intravenskim imunoglobulinima (IVIg) te postupno rezultirao
punim neurolo{kim oporavkom.
Introduction
Studies have shown that serum samples from patients
with Miller Fisher syndrome (MFS), Guillain-Barré syn-
drome (GBS), Bickerstaff's brainstem encephalitis (BBE)
and acute ophtalmoparesis often have positive anti-GQ1b
antibodies [1]. 
These results might suggest that there is a common un-
derlying mechanism in the pathogenesis of these diseases.
The importance of these findings lies in the fact that it
could bring us closer to understanding the etiological
mechanisms behind these conditions, as well as to expand
the well known and effective therapy used for GBS to oth-
er related disorders [1]. 
The aim of this case report was to present challenges in
diagnosis and treatment of a young patient with overlap-
ping GBS and MFS syndrome.
Case report
Patient information and clinical findings
A31-year-old man presented in our emergency depart-
ment due to the sudden onset of binocular diplopia. One
week prior to the symptom onset he had diarrhea. Other
past medical history didn't reveal any significant diseases
other than psoriasis.
The physical examination was unremarkable, while
the neurological examination revealed diplopia with sus-
pected right abducens nerve palsy and right ptosis with
preserved pupil function. Other than that, the patient didn't
have any sensory or motoric deficits nor signs of respira-
tory insufficiency.
The examination was followed by the computed to-
mography (CT) of the brain which was unremarkable.
Full blood count, serum electrolytes, urea and liver en-
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the patient from the mechanical ventilation. However,
there was no other clinical improvement and since the
slight progress of the motoric deficit in the arms was ob-
served, therapy with intravenous immunoglobulin (Octagam)
was indicated in dose 2g/kg over 5 days. 
Follow-up and Outcomes
During the hospitalisation, intensive physiotherapy
and speech therapist treatment were continuously imple-
mented. The first signs of recovery were observed one
month after admission in the reduction of facial palsy, pto-
sis, ophthalmoplegia, dysarthria and in the improvement
of the muscle strength in the right (3/5) and in the left arm
(2/5) and in both legs (3/5). Three months after the admis-
sion, the patient was discharged from the hospital and re-
ferred to stationary rehabilitation. 
The first follow-up after the discharge from the hospi-
tal was two months later. The neurological exam revealed
significant improvement with residual gait ataxia, dys-
arthria and slight weakness of the proximal musculature of
both arms (motor strength in the upper extremities 3/5,
motor strength in the lower extremities 4/5).
On the second follow-up, four months after the dis-
charge, the patient was independently mobile, without
speech disturbances and with the residual mild motoric
deficit of the left arm (motor strength 3/5). 
Discussion
The typical presentation of a patient with MFS in-
cludes a triad of symptoms: ophthalmoplegia, ataxia and
areflexia. MSF is considered to be a variant of GBS since
one-fourth of the patients with MFS will develop some
kind of muscular weakness [2]. Furthermore, the antibod-
ies against GQ1b that are present in most cases of MFS,
can also be found in patients with GBS that present with
ophthalmoplegia [1, 3, 5]. In addition, BBE, that repre-
sents features of MFS with accompanying encephalopathy
and hyperreflexia, also has been associated with anti-
GQ1b antibodies that can be found in up to 66 % of the cas-
es and can respond well to intravenous immunoglobulin
(IVIG) and plasma exchange [1, 4, 5].
This issue has been recognized and the term anti-GQ1b
IgG antibody syndrome was formed in order to explain the
nosological relationship between these conditions [2]. 
In overlapping cases, such as MFS and GBS, or MFS
and BBE, the clinical features may cause confusion so that
making a correct diagnosis can be challenging for clini-
cians, especially when taking into consideration that vari-
ous forms of overlapping syndromes are increasingly re-
ported [5]. 
In our case, the patient initially showed symptoms of
MFS that progressed to GBS in the first week of the symp-
zymes profile were normal. After the initial diagnostics
were performed, the patient was admitted to the Depart-
ment of Neurology.  
During the first days after hospitalization, the clinical
state continued to worsen with the progression of neuro-
logical deficit affecting multiple cranial nerves presenting
in dysphagia, dysarthria, bilateral facioparesis and bilater-
al ophthalmoplegia, the absence of myotatic reflexes,
paresthesias in the hands and feet, tetraparesis (muscle
strength in the left arm and in both legs 1/5, muscle
strength in the right arm 2/5). First signs of dysautonomia
were observed on the 4th day after the admission when the
patient developed urinary retention. Later on, he manifest-
ed other signs of autonomic dysfunction that included
bradycardia, orthostatic hypotension and excessive
sweating. 
Diagnostic assessment
Initial negative CT scan in the emergency department
was followed with intrahospital magnetic resonance (MR)
of the brain and the magnetic resonance angiography
(MRA) of the brain vessels on the second day after the ad-
mission. Neither showed any significant pathological
findings.
The lumbar puncture was performed on the third day
of the admission that showed increased protein level (0,61
g/L) with normal cell counts (2 cells) and normal CSF glu-
cose levels. 
Electroneurography performed on day 7 of the illness
revealed moderate loss of motoneurons in all examined
muscle groups. Neurographic analysis showed low ampli-
tude sensory nerve action potentials (SNAP) in all sensory
nerves, left ulnar nerve conduction block, absent F waves
of both ulnar nerves and right peroneal nerve, as well as
the absence of the H reflex and reduced nerve conduction
velocity of motor fibers of the left ulnar nerve and both
peroneal nerves.
Serum tests for antiganglioside antibodies were sent
for analysis and came positive for anti-GD1b and anti-
GQ1b.
Therapeutic interventions
Considering the clinical presentation of overlapping
Miller Fisher and Guillain-Barré syndrome, treatment
with plasma exchange was initiated. Despite the treat-
ment, the clinical state continued to worsen to the state of
the respiratory arrest on the 6
th
day of the hospitalisation
due to which the patient was urgently intubated and me-
chanically ventilated.
In total, five plasma exchanges were given on alternate
day schedule which gradually resulted in the separation of
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toms onset. Since there were no signs of consciousness
disturbances and his electroencephalography (EEG) and
brain MR were normal, we have ruled out Bickerstaff
brainstem encephalitis from the diagnosis. 
There are no early predictors that could be used to dif-
ferentiate which patient initially diagnosed as MFS will
later on develop MFS-GBS overlap syndrome. It has been
noticed, however, that the progression occurs within one
week from the disease onset, as it was in our case [6].
No randomized controlled trial has been performed in-
vestigating the efficacy of IVIg or plasma exchange in
MFS or MFS-GBS overlap syndrome [7]. However, it is
considered that extrapolating GBS data to the population
of MFS patients whose disease course is complicated is
justified [7]. 
Our patient was initially treated with plasma exchange.
However, since there was no adequate response after five
plasma exchanges and the slight worsening of symptoms
was observed, we have indicated therapy with intravenous
immunoglobulin that eventually led to almost full recov-
ery. The trial of the combination of both treatments is al-
ready present in clinical practice for over 25 years [8]. The
rationale for this treatment in patients with insufficient
clinical response might be that these treatments probably
have different immunomodulatory effects that may influ-
ence the treatment efficacy in individual patients [9]. 
The optimal management for most severe cases of
GBS remains uncertain [8]. On-going studies are trying to
investigate if it is justified to switch to another immuno-
modulatory therapy or repeat treatment in patients who
deteriorate after receiving first-line immunomodulatory
therapy [10]. Currently known data show no difference in
outcomes of patients that received either PE, IVIg or PE
followed by IVIg [10]. 
Regarding the treatment with PE after IVIg, there was
one study that reported that patients who received treat-
ment with IVIg followed by PE had worse outcomes than
patients that received IVIg alone [11]. These results could
be explained by PE washing out IVIg and in that way pre-
venting therapeutic effects of IVIg [11]. 
This suggests that current clinical practice requires
further investigations to clinical predictors of early deteri-
oration and to define the treatment modalities in patients
with anti-GQ1b overlapping syndromes. 
References
[1] Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome:
clinical and immunological range. J Neurol Neurosurg Psychiatry
2001;70:50–55.
[2] Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical fea-
tures and prognosis of Miller Fisher syndrome. Neurology 2001;
56:1104 –1106.
[3] Carpo M, Pedotti R, Allaria S, Lolli F, Mata S, Cabaletti G, et al.
Clinical presentation and outcome of Guillain-Barré and related
syndromes in relation to anti-ganglioside antibodies. J Neurol Sci
1999;168:78 – 84.
[4] Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al.
Bickerstaff's brainstem encephalitis: clinical features of 62 cases
and a subgroup associated with Guillain-Barré syndrome. Brain
2003;126:2279 –2290.
[5] Lo YL. Clinical and immunological spectrum of the Miller Fisher
syndrome. Muscle Nerve 2007; 36:615–27.
[6] Verboon C, van Berghem H, van Doorn PA, Ruts L, Jacobs BC.
Prediction of disease progression in Miller Fisher and overlap syn-
dromes. J Peripher Nerv Syst 2017;22:446–450.
[7] Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ (2007).
Treatment for Fisher syndrome, Bickerstaff's brainstem en-
cephalitis and related disorders. Cochrane Database Syst Rev:
CD004761.
[8] Taylor CJ, Hirsch SJ, Howard RS. Changes in the severity and
subtype of Guillain-Barré syndrome admitted to a specialist
Neuromedical ICU over a 25 year period. J Neurol 2017;264:
564–569.
[9] Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in
Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2017;
88:346–352.
[10] Randomised trial of plasma exchange, intravenous immunoglobu-
lin, and combined treatments in Guillain-Barré syndrome. Plasma
Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Lancet 1997;349:225–30.
[11] Oczko-Walker M, Manousakis G, Wang S, et al. Plasma exchange
after initial intravenous immunoglobulin treatment in Guillain-
Barré syndrome: critical reassessment of effectiveness and cost-
efficiency. J Clin Neuromuscul Dis 2010;12:55–61.

